Hepatitis C

More News

February 12th 2020

Discontinuation of New Hepatitis C Drugs Among Medicare Patients

Jeah Jung, PhD, MPH Ping Du, MD, PhD Roger Feldman, PhD Thomas Riley III, MD

Real-world discontinuation of hepatitis C drugs was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics.

December 13th 2019

Cost Burden of Hepatitis C Virus Treatment in Commercially Insured Patients

Christine Y. Lu, PhD Dennis Ross-Degnan, ScD Fang Zhang, PhD Robert LeCates, MA Caitlin Lupton, MSc Michael Sherman, MD Anita Wagner, PharmD

Rates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health plan bore 99% of spending on HCV medications.

August 30th 2019

What We're Reading: State-Based ACA Exchange; Surgeon General on Marijuana Use; HCV Drugs and Liver Impairment

AJMC Staff

Maine wants to take more control over its Affordable Care Act marketplace; Surgeon General Jerome Adams, MD, MPH, has issued an advisory against marijuana use in young people and pregnant people; the FDA is warning of rare occurrences of serious liver injury from use of 3 hepatitis C virus (HCV) drugs.

August 16th 2019

5 Findings From the August 2019 Issue of AJMC®

Christina Mattina

The August issue of The American Journal of Managed Care® (AJMC®) featured research on surprise medical billing policies, social determinants of health, and the value of chimeric antigen receptor T-cell therapies, among other topics. Here are 5 findings from research published in the issue.

August 13th 2019

Late Diagnosis of Hepatitis C Virus Infection, 2014-2016: Continuing Missed Intervention Opportunities

Anne C. Moorman, MPH Jian Xing, PhD Loralee B. Rupp, MSE Stuart C. Gordon, MD Mei Lu, PhD Philip R. Spradling, MD Joseph A. Boscarino, PhD Mark A. Schmidt, PhD Yihe G. Daida, PhD Eyasu H. Teshale, MD for the CHeCS Investigators

Late hepatitis C virus infection diagnosis points to a need for earlier screening and treatment before the onset of severe liver disease leading to high cost and diminished outcomes.

July 12th 2019

Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017

Naoky Tsai, MD Bruce Bacon, MD Michael Curry, MD Steven L. Flamm, MD Scott Milligan, PhD Nicole Wick, AS Zobair Younossi, MD Nezam Afdhal, MD

From 2013 to 2017, the population of US patients prescribed treatment for chronic hepatitis C virus (HCV) changed, becoming predominantly treatment-naïve and having received care in nonacademic centers.

June 18th 2019

Assessing the Burden of Illness of Chronic Hepatitis C and the Impact of Direct-Acting Antiviral Use on Healthcare Costs in Medicaid

M. Christopher Roebuck, PhD Joshua N. Liberman, PhD

June 13th 2019

What We're Reading: Washington HCV Subscription Model; AMA Against Medicare for All; Medically Assisted Suicide

AJMC Staff

CMS has approved Washington state’s proposal for a subscription model to purchase hepatitis C virus (HCV) drugs; the American Medical Association (AMA) voted against a measure that would drop its decades-long stance against single-payer healthcare proposals; Maine has become the eighth state to legalize medically assisted suicide.

June 6th 2019

Evidence Suggests HCV Could Be a Risk Factor for Parkinson Disease

Wallace Stephens

Epidemiological evidence suggests that hepatitus C infection may be a risk factor for developing Parkinson disease.

May 24th 2019

Suspension of a Rural Syringe Service Program Increased Risks of HIV and HCV Acquisition

Wallace Stephens

After a rural syringe service program was indefinitely suspended, individuals who inject drugs had a greater risk of contracting HIV and hepatitus C virus.

February 28th 2019

AJMC® Research Roundup: February 2019

Here are 5 interesting findings from the February 2019 issue of AJMC®.

February 15th 2019

5 Findings From the February 2019 Issue of AJMC®

Christina Mattina

The February 2019 issue of The American Journal of Managed Care® (AJMC®) featured research on value-based arrangements, effects of cesarean delivery data, and more. Here are 5 findings from the research published in the issue.

February 8th 2019

Abuse-Deterrent Version of OxyContin Driving Spike in Hepatitis C Infection

Jaime Rosenberg

In 2010, OxyContin was reformulated and an abuse-deterrent version was introduced, leading to an increase in heroin use and subsequent rise in hepatitis C infection rates.

February 7th 2019

Impact of Hepatitis C Virus and Insurance Coverage on Mortality

Haley Bush, MSPH James Paik, PhD Pegah Golabi, MD Leyla de Avila, BA Carey Escheik, BS Zobair M. Younossi, MD, MPH

The Medicaid population has significantly higher hepatitis C virus (HCV) prevalence and mortality rates than patients with private insurance. These data must be considered when policy makers assess providing additional support to Medicaid programs for HCV elimination.

December 26th 2018

Real-World HCV Study Finds Sofosbuvir/Ledipasvir Safe, Effective

Samantha DiGrande

A recent study looked to evaluate the real-world effectiveness of hepatitis C virus (HCV) treatment in patients with genotype 1 (HCV-1) infection.

December 26th 2018

Oregon Medicaid Program to End HCV Treatment Rationing in 2019

Allison Inserro

Patients with the hepatitis C virus (HCV) who are on Medicaid in Oregon can expect to receive curative treatment in 2019 without having to wait for liver damage to set in.

December 22nd 2018

Glecaprevir/Pibrentasvir Is Safe, Effective in Treatment of HCV in Real-World Setting

Samantha DiGrande

The efficacy and safety of glecaprevir/pibrentasvir (G/P, sold as Mavyret) in the treatment of hepatitis C virus (HCV) has previously only been investigated in clinical trials. Thus far, no real-world data had been available until a group of researchers looked to investigate the efficacy and safety of G/P in a real-world setting in Italy.

December 21st 2018

HCV Prevalence Higher in West and Appalachian US States

Samantha DiGrande

Hepatitis C virus (HCV) is the most frequently reported bloodborne infection in the United States, and prevalence has increased in recent years. Researchers recently sought to estimate the prevalence of HCV at the state level in order to more accurately guide prevention and care efforts.

December 15th 2018

Sofosbuvir-Based Therapy Safe in Patients With HCV and Certain Cancers

Samantha DiGrande

Existing data are limited on the treatment of chronic hepatitis C virus (HCV) in patients with cancer. In a study recently published in Nature, researchers sought to evaluate the safety and efficacy of a sofosbuvir (Sovaldi)-based therapy in this patient population.

December 14th 2018

Study Finds HCV Infection Increases 10-Year Risk of Cardiovascular Disease

Surabhi Dangi-Garimella, PhD

A combined analysis of data gathered from the Canadian Health Measures Survey and the US–National Health and Nutrition Examination Survey found a 2.5% to 3.5% increase in the 10-year risk of cardiovascular disease in patients with a hepatitis C virus (HCV) infection.

December 6th 2018

HBV Reactivation a Serious Adverse Effect of DAAs in the Treatment of HCV

Surabhi Dangi-Garimella, PhD

A kidney transplant patient treated with direct-acting antivirals (DAAs) for a chronic hepatitis C virus (HCV) infection showed reactivation of the hepatitis B virus (HBV), which proved fatal. The authors of the report recommend a call to action for including HBV testing as part of the patient’s work-up in transplant recipients who are on immunosuppressants, especially in the context of abnormal liver tests.

December 1st 2018

Perinatal Exposure to HCV Leads to Earlier Cirrhosis

Samantha DiGrande

A recent retrospective review of patients who contracted hepatitis C (HCV) in childhood found that those with perinatal infection developed cirrhosis earlier than other risk groups.

November 26th 2018

Patients With Chronic Kidney Disease Infected With HCV Have Low Resistance to Direct-Acting Antivirals

Surabhi Dangi-Garimella, PhD

To better understand the characteristics of patients with chronic kidney disease who require hemodialysis or renal transplant, researchers in Brazil evaluated the prevalence of resistance-associated substitutions to direct-acting antivirals in this population who also carry the hepatitis C virus (HCV).

November 22nd 2018

Universal HCV Screening Economical Over Risk-Based Screening in Pregnant Women

Surabhi Dangi-Garimella, PhD

According to a new study presented at The Liver Meeting, combining universal screening for the hepatitis C virus (HCV) with reflex RNA PCR in pregnant women is more cost-effective than risk-based screening.

November 17th 2018

Shortening Treatment Time Maintains Efficacy, Saves Costs in Hepatitis C

Samantha DiGrande

A new study found that in 50% of patients, the standard 12-week treatment regimen for hepatitis C could be shortened to as few as 6 weeks without compromising efficacy.

November 14th 2018

ANCHOR Study Finds High Adherence Rate in Patients With Hepatitis C Who Inject Opioids

Surabhi Dangi-Garimella, PhD

Research presented at The Liver Meeting, held by the American Association for the Study of Liver Diseases, found high rates of adherence, treatment completion, and sustained virologic response among patients infected with the hepatitis C virus (HCV) who inject drugs. These findings led authors to recommend inclusion of this subset of patients in HCV treatment programs.

November 10th 2018

Antiviral Therapy Prevents HCV in Patients Receiving Infected Donor Hearts

Jaime Rosenberg

Preliminary data from a new study has demonstrated that pre-emptive administration of pan-genotypic, direct-acting antiviral therapy prevents hepatitis C virus (HCV) infection in HCV-negative cardiac transplant patients receiving donor hearts infected with the virus.

September 11th 2018

Hepatitis C Care Cascade Among Persons Born 1945-1965: 3 Medical Centers

Joanne E. Brady, PhD Claudia Vellozzi, MD, MPH Susan Hariri, PhD Danielle L. Kruger, BA David R. Nerenz, PhD Kimberly Ann Brown, MD Alex D. Federman, MD, MPH Katherine Krauskopf, MD, MPH Natalie Kil, MPH Omar I. Massoud, MD Jenni M. Wise, RN, MSN Toni Ann Seay, MPH, MA Bryce D. Smith, PhD Anthony K. Yartel, MPH David B. Rein, PhD

In this analysis of patients with newly diagnosed hepatitis C, linkage to care was largely successful in the 1945-1965 birth cohort, but treatment initiation remained low. Check out our website’s new table/figure pop-up feature! Click on the name of a table or figure in the text to see it in your browser.

August 16th 2018

Ohio Tells Medicaid PBMs That 2019 Will Be a Time for Transparent Contracts

Allison Inserro

Less than 2 months after receiving a report showing that pharmacy benefit managers (PBMs) in Ohio billed taxpayers 8.8% more for medications used by those in the state’s Medicaid program, the state this week said it is ending its contracts with all of its PBMs and starting over in transparent contracts.

August 10th 2018

Evaluating HCV Screening, Linkage to Care, and Treatment Across Insurers

Karen Mulligan, PhD Jeffrey Sullivan, MS Lara Yoon, MPH Jacki Chou, MPP, MPL Karen Van Nuys, PhD

An optimized hepatitis C virus screening and linkage-to-care process reduces the number of patients lost to follow-up and improves linkage to care for Medicare, Medicaid, and commercially insured patients.

1 2 3 4 5 6 7 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions

Hepatitis C

Latest News

More News